Found 4 clinical trials
A Trial of Neoadjuvant mXELOXIRI Versus CRT in the EMVI Positive LARC
Extramural Vascular Invasion Positive(EMVI+) is a high risk of distant metastasis for locally advanced rectal cancer(LARC) after resection. The study is to evaluate the efficacy and safety of XELOXIRI as neoadjuvant chemotherapy alone for EMVI+ LARC in contrast to the efficacy of standard Chemoradiotherapy (CRT).
- 0 views
- 05 Aug, 2020
Neoadjuvant mFOLFOXIRI Plus Bevacizumab With Selective Radiotherapy in Patients With High-Risk Locally Advanced Rectal Cancer
Multimodality treatment that comprises preoperative fluoropyrimidine with concurrent radiotherapy followed by total mesorectal excision (TME) surgery and adjuvant fluoropyrimidine-based chemotherapy is recommended as a standard treatment of patients with stage II/III rectal cancer.
- 0 views
- 16 Feb, 2024
- 1 location
SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer
TASOX can be safely and efficaciously delivered after short course radiation, resulting in significant pathologic downstaging, allowing for an R0 pelvic resection, and providing local control in appropriately selected stage II/III rectal cancer patients treated with contemporary TME-based surgery.
- 0 views
- 05 Aug, 2020
Urinary and Sexual Dysfunctions Evaluation After Rectal Resection
Secondary endpoints will be: to investigate which technique (open, robotic, laparoscopic and trans-anal total mesorectal excision (TaTME)) more favorably correlate with urinary and sexual functions after radiochemotherapy (NAD+); the comparison of both the urinary and sexual dysfunction incidence on the base of the distance of the rectal tumor from the …
- 0 views
- 05 Aug, 2020